Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients
- 31 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (8), 1565-1576
- https://doi.org/10.1007/s00262-020-02563-2
Abstract
Purpose Tumor microenvironment is important in the progression of clear cell renal cell carcinoma (ccRCC), and its prognostic value is still unclear. Recent reports demonstrated tumor-infiltrating CD39(+)CD8(+) T cells are abundant, but their function remains obscure. We aim to assess clinical value of CD39(+)CD8(+) T cells and seek a potential therapeutic target in ccRCC. Experimental design We immunohistochemically evaluated clinical value of CD39(+)CD8(+) T cells in a retrospective Zhongshan Hospital cohort of 243 ccRCC patients. Fresh tumor samples (n = 48), non-tumor tissues and peripheral blood for flow cytometry analyses were collected to analyze immune cell functions from Zhongshan Hospital. The survival benefit of tyrosine kinase inhibitors (TKIs) in this subpopulation was evaluated. Kaplan-Meier analysis and COX regression model were applied for survival analyses. Bioinformatics analysis performed in TCGA KIRC cohort and the scRNA-seq cohort. Results We found that accumulation of CD39(+)CD8(+) T cells indicated poor prognosis (p < 0.0001) and indicated therapeutic benefit of TKIs therapy (p = 0.015). CD39(+)CD8(+) T cells showed decreased TNF-alpha and IFN-gamma with elevated PD-1 and TIM-3 expression. Further analysis of tumor-infiltrating immune cell landscape in the ccRCC revealed the positive correlation between CD39(+)CD8(+) T cells and Tregs (p = 0.037) and M2-polarized macrophages (p < 0.0001). Finally, inhibition of CD39 partially restores the anti-tumor function of CD8(+) T cells. Conclusions High CD39(+)CD8(+) T cells indicated poor prognosis in ccRCC, due to impaired anti-tumor function of CD39(+)CD8(+) T cells and indicated therapeutic benefit of TKIs therapy. [GRAPHICS] .Funding Information
- National Natural Science Foundation of China (81671628, 81702496, 31770851,81871306,81872082,81902556,81902563, 81902898, 81974393, 81702497, 81702805, 81772696)
- Shanghai Municipal Population and Family Planning Commission (20174Y0042)
- National Key R&D Program of China (2017YFC0114303)
- Shanghai Municipal Natural Science Foundation (16ZR1406500,17ZR1405100, 19ZR1431800)
- Guide Project of Science and Technology Commission of Shanghai Municipality (17411963100)
This publication has 31 references indexed in Scilit:
- Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysisBMC Cancer, 2011
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Regulated Catalysis of Extracellular Nucleotides by Vascular CD39/ENTPD1 Is Required for Liver RegenerationGastroenterology, 2008
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature reviewCancer Treatment Reviews, 2008
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Renal-Cell CarcinomaThe New England Journal of Medicine, 2005
- Cancer vaccines: between the idea and the realityNature Reviews Immunology, 2003
- An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign ScoreJournal of Urology, 2002